Experimental malaria antibody protects infants but may interfere with vaccine
An experimental malaria antibody called L9LS provided strong protection to infants in Mali during the six-month malaria season, according to a clinical trial presented at the American Society of Tropical Medicine and Hygiene annual meeting. However, the antibody appeared to interfere with how infants' immune systems responded to the R21 malaria vaccine, which is widely used in Mali.
The Phase Ib trial tested L9LS, a monoclonal antibody developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), in infants as young as one month old. Researchers wanted to test the antibody in very young children because they cannot receive malaria vaccines until at least five months old, leaving them vulnerable during peak malaria transmission times.
The antibody protected infants with 78% efficacy against malaria infection and was safe, according to the trial results. However, because it interfered with the R21 vaccine's effectiveness, researchers said they are pausing plans for a larger trial with infants. The antibody had shown a strong safety and effectiveness record in earlier trials with older children in Mali and Kenya.
Researchers said they will continue studying whether L9LS could help protect children who remain at risk of malaria after they have completed the R21 vaccine series.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.
